Brexpiprazole (Rexulti®) for “agitation associated with dementia due to Alzheimer’s disease”

This article was first published on January 28, 2024. It was last reviewed, updated, or edited on January 30, 2024. In May 2023, the FDA approved an additional indication for brexpiprazole (Rexulti®). The wording of the indication states: “Treatment of agitation associated with dementia due to Alzheimer’s disease”. The special significance of this FDA approval was…